NEU 2.81% $18.65 neuren pharmaceuticals limited

Ann: 2023 Annual Report to shareholders, page-162

  1. 124 Posts.
    lightbulb Created with Sketch. 113
    i I think that is a lot of invisible dots connected to reach a pessimistic conclusion.

    Even if it were possible the management team of Neuren thought of doing this (can't believe they would contemplate it anyway) what material difference does it make in the end? Nada.

    i'm sticking to the simple notion that 2591 is a very effective drug that I hope can translate into a positive impact on PH sufferers.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.